Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
Reports an Apnea–Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis [...] Read more »
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
Reports an Apnea–Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis [...] Read more »
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
Expect to report DREAM U.S. pivotal study efficacy and safety data by early April
Achieved record [...] Read more »
Nyxoah Publie ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Exercice 2023
Les données d'efficacité et de sécurité [...] Read more »
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Mont–Saint–Guibert, [...] Read more »
Nyxoah Participera à la 34ème Oppenheimer Annual Healthcare MedTech & Services Conference
Read more »
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
Mont–Saint–Guibert, Belgium – February 15, 2024, [...] Read more »
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l'Exercice 2023 le 5 Mars 2024
Mont–Saint–Guibert, Belgique – 15 [...] Read more »
Nyxoah Annonce ses Priorités Stratégiques pour 2024
Mont–Saint–Guibert, Belgique – 17 janvier 2024, 22h05 CET / 16h05 ET – Nyxoah SA [...] Read more »
Nyxoah Announces 2024 Strategic Priorities
Mont–Saint–Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: [...] Read more »
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
Mont–Saint–Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – [...] Read more »